Sugi Predict

Sugi Predict / Compounds / SCHEMBL554651

SCHEMBL554651

SCHEMBL554651

CC(C)(C)OC(=O)N1CCOC[C@@H]1CN

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ RECQL P46063 1/20 0.43
▸ ATM Q13315 2/20 0.40
▸ IL1B P01584 1/20 0.40
▸ P2RX7 Q99572 1/20 0.40
▸ PDK1 Q15118 4/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ PDK3 Q15120 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.34
▸ CTSK P43235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL553583 1.00 USP2 (0.47) USP2SMN1; SMN2RECQLATMIL1B
SCHEMBL553582 1.00 USP2 (0.47) USP2SMN1; SMN2RECQLATMIL1B
Hydrochloric Acid SCHEMBL28718255 0.99 USP2 (0.46) USP2SMN1; SMN2RECQLATMIL1B
SCHEMBL31283997 0.89 USP2 (0.45) USP2SMN1; SMN2RECQLATMIL1B
SCHEMBL18989030 0.87 USP2 (0.50) USP2SMN1; SMN2RECQLATMIL1B
SCHEMBL307099 0.87 PDK1 (0.49) USP2SMN1; SMN2RECQLATMIL1B
SCHEMBL305110 0.87 PDK1 (0.49) USP2SMN1; SMN2RECQLATMIL1B
SCHEMBL20371626 0.87 USP2 (0.49) USP2SMN1; SMN2RECQLATMIL1B
SCHEMBL14417217 0.87 USP2 (0.49) USP2SMN1; SMN2RECQLATMIL1B
SCHEMBL3641031 0.87 USP2 (0.49) USP2SMN1; SMN2RECQLATMIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 — — US disclosed
US-20250127801-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-04-24 — — US disclosed
WO-2025080850-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-04-17 — — WO disclosed
CN-119032089-A Oxadiazole compounds, pharmaceutical compositions containing them and their use 勤浩医药（苏州）有限公司 2024-11-26 — — CN disclosed
WO-2022194237-A1 QUINOLINE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF AUTOIMMUNE DRUG 成都百裕制药股份有限公司 2022-09-22 — — WO disclosed
EP-3356348-B1 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS SENTINEL ONCOLOGY LTD (GB) 2021-05-05 — — EP disclosed
EP-3356348-B1 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS SENTINEL ONCOLOGY LTD (GB) 2021-05-05 — — EP disclosed
CN-108473472-B 2-aminoquinazoline derivatives as P70S6kinase inhibitors 圣提内尔肿瘤学有限公司 2021-02-12 — — CN disclosed
US-10730882-B2 2-aminoquinazoline derivatives as P70S6 kinase inhibitors SENTINEL ONCOLOGY LIMITED (GB) 2020-08-04 — — US disclosed
US-10730882-B2 2-aminoquinazoline derivatives as P70S6 kinase inhibitors SENTINEL ONCOLOGY LIMITED (GB) 2020-08-04 — — US disclosed
US-20180370975-A1 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS SENTINEL ONCOLOGY LIMITED (GB) 2018-12-27 — — US disclosed
EP-3356348-A1 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS Sentinel Oncology Limited (GB) 2018-08-08 — — EP disclosed
US-20160176906-A1 Chemical Compounds ASTRAZENECA AB (SE) 2016-06-23 — — US disclosed
US-9248140-B2 Chemical compounds ASTRAZENECA AB (SE) 2016-02-02 — — US disclosed
US-20150328239-A1 Chemical Compounds ASTRAZENECA AB (SE) 2015-11-19 — — US disclosed
US-9018381-B2 Chemical compounds ASTRAZENECA AB (SE) 2015-04-28 — — US disclosed
US-20130310344-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ASTRAZENECA AB (UK) 2013-11-21 — — US disclosed
EP-2601177-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS AstraZeneca AB (SE) 2013-06-12 — — EP disclosed
US-20120035134-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-09 — — US disclosed
WO-2012017251-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ASTRAZENECA AB (SE) 2012-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180370975-A1 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS RPS6KA1, MTOR, RPTOR USP2 3263/4885SMN1; SMN2 227/4885RECQL 2068/4885
US-20120035134-A1 CHEMICAL COMPOUNDS BCL2, BCL2L1, BAX USP2 2802/4885SMN1; SMN2 4406/4885RECQL 1901/4885
US-20250127801-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF SDHA, SDHB, DPYD USP2 3590/4885SMN1; SMN2 2987/4885RECQL 445/4885
US-20150328239-A1 Chemical Compounds BCL2, BCL2L1, BAX USP2 2802/4885SMN1; SMN2 4406/4885RECQL 1901/4885
US-20160176906-A1 Chemical Compounds BCL2, BCL2L1, BAX USP2 2802/4885SMN1; SMN2 4406/4885RECQL 1901/4885
US-20130310344-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BCL2, BAX, BCLAF1 USP2 1616/4885SMN1; SMN2 2613/4885RECQL 3333/4885
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF CGAS, GMPS, PRKG1 USP2 3480/4885SMN1; SMN2 3638/4885RECQL 51/4885
US-10730882-B2 2-aminoquinazoline derivatives as P70S6 kinase inhibitors RPS6KA1, MTOR, RPTOR USP2 3263/4885SMN1; SMN2 227/4885RECQL 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback